Improving Breast Cancer Related Lymphedema and Upper Extremity Dysfunction: Why Multidisciplinary Care Matters
This activity begins with discussion on optimal ways to identify high risk patients, approaches to patient education for all women, with a specific focus on those women disproportionately affected by BCRL/UED, and clinical workflows for high risk patients/those who have already developed BCRL/UED
Category
  • Breast
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
How to Implement CT-guided Adaptive Radiation in Your Clinic: Practical Lessons and Streamlined Approaches Learned From Clinical Trials
Adaptive radiation therapy (RT) is an innovative treatment approach that is entering radiation oncology practice for the treatment of a variety of malignancies.
Category
  • Adaptive RT
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Sexuality After Cancer Therapy
Patient fertility and sexual complications have few data available from clinical trials. It is noteworthy that the subject is infrequently discussed in institutional peer reviews/ M&M unless there is a Risk Management overlay.
Category
  • Breast
  • Genitourinary
  • Gynecologic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Treating Stage IV Breast Cancer: Who, What, Where and When?
Significant advances in systemic treatment options have positively impacted breast cancer survivorship.
Category
  • Breast
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Perspectives from a Physicist, Biologist and Clinician: Unrealized Opportunities in Spatially Fractionated Radiotherapy
We have observed the evolution of spatially fractionated radiotherapy (SFRT) primarily to manage metastatic cancer patients in the palliative care setting. Given recent advances in how SFRT can be delivered, can this therapeutic modality be optimized beyond the palliative care setting?
Category
  • Physics
  • Radiobiology
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Updates and Challenging Cases in Pediatric Neuroblastoma and Wilms Tumor
Updates in the treatment of pediatric neuroblastoma and Wilms Tumor are presented, highlighting recent practice-changing publications and evolving study questions.
Category
  • Central Nervous System
  • Pediatric
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Integration of Radiotherapy with New Systemic Treatments for Breast Cancer
There is a significant gap in the knowledge and practice of integrating novel systemic therapies with radiotherapy in breast cancer management, particularly due to limited clinical trial data on their combined use.
Category
  • Breast
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Molecular Intelligence in Breast Cancer Radiation Therapy
Molecular testing is an integral component of multidisciplinary management of breast cancer. Recent evidence underscores the importance of molecular assays in radiation therapy decision making.
Category
  • Breast
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Principles and Skills of Brachytherapy: Resident-Focused Essentials
Brachytherapy is an invaluable tool in the radiation oncologist's toolbox, but the perceived proficiency among residents has been variable and there is great diversity in how programs deliver brachytherapy.
Category
  • Brachytherapy
  • Genitourinary
  • Gynecologic
Format
  • Sessions onDemand
Credits
  • 1.50 Certificate of Attendance
Cost $149.00
ASTRO/SNMMI Joint Session: Unlocking Success in Radiopharmaceutical Therapy: Collaboration between Radiation Oncology, Nuclear Medicine and Industry
Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.
Category
  • Radiopharmaceutical Therapy
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00

Pages